Ask AI
ProCE Banner Activity

What’s Next in SCLC: Expert Perspectives on Practice-Changing Updates From 2025 Global Congresses

Slideset

This downloadable slideset highlights the latest clinical breakthroughs and management strategies for treating patients with SCLC from 2025 global congresses, ranging from first-line therapies to relapsed and end-stage treatment options.  

Released: April 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational funding provided by Amgen and Boehringer Ingelheim Pharmaceuticals, Inc.

Amgen

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key efficacy and safety findings from the 2025 ASCO, ESMO, and WCLC meetings that inform first-line and maintenance treatment decisions for patients with limited-stage and extensive-stage SCLC

  • Evaluate the role of immunotherapy in the evolving management of limited-stage and extensive-stage SCLC, including new evidence supporting consolidation or maintenance strategies

  • Analyze recent data on lurbinectedin, DLL3-targeted bispecific antibodies, and antibody–drug conjugates to support optimal sequencing strategies for patients with relapsed/refractory SCLC

  • Interpret emerging biomarker evidence, such as SLFN11 and DLL3 expression, to determine its potential role in treatment personalization for patients with SCLC

  • Apply clinical best practices for mitigating immune-related and agent-specific adverse events associated with novel agents in the SCLC treatment landscape

  • Integrate new evidence into individualized treatment plans by considering performance status, comorbidities, and quality-of-life considerations across lines of therapy